top of page

Item List

Business Wire
Endeavor BioMedicines Partners with xCures

Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, and xCures, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence, today announced a partnership that gives patients enrolling in Endeavor's clinical trials access to the xCures platform to find the best available treatment options suited to their individual tumor profile. The partnership helps identify patients whose cancers harbor the PTCH1 mutation and may be eligible for Endeavor’s clinical trial. The xCures platform also enables patients to find more suitable treatment options if they are ineligible.

Recent Posts

Portfolio Company


Clario and Strados Labs partner to bring new pulmonary endpoints to respiratory ...

Strados Labs

Wavemaker 360 News


Wavemaker Three-Sixty Health Announces 2023 Council of Strategic Advisors to Sup ...


Wavemaker 360 News


MedTech Color investing in Black, brown leaders in medical technology world ...

Fox 11 News

surf break copy_edited_edited.jpg
bottom of page